Enlivex Therapeutics (ENLV) News Today $0.95 -0.03 (-2.67%) Closing price 05/27/2025 03:57 PM EasternExtended Trading$1.03 +0.08 (+8.43%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ENLV Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Enlivex Selected to Present at Israeli BioMed 2025 ConferenceMay 20, 2025 | globenewswire.comEnlivex Therapeutics to Showcase Allocetra's Potential in Osteoarthritis at OARSI 2025 World CongressApril 23, 2025 | globenewswire.comEnlivex enrols all patients in Phase II stage of knee osteoarthritis trialApril 23, 2025 | msn.comEnlivex Therapeutics Completes Patient Enrollment in Phase II Trial of Allocetra™ for Knee OsteoarthritisApril 23, 2025 | nasdaq.comEnlivex completed enrollment of patients in Phase II trial of AllocetraApril 22, 2025 | markets.businessinsider.comEnlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee OsteoarthritisApril 21, 2025 | globenewswire.comIs Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Invest In Growth?April 7, 2025 | finance.yahoo.comEnlivex Therapeutics doses first patient in Phase I trial of AllocetraApril 4, 2025 | markets.businessinsider.comEnlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ OsteoarthritisApril 3, 2025 | globenewswire.comEnlivex Therapeutics Releases 2024 Financial StatementsMarch 31, 2025 | tipranks.comEnlivex Therapeutics price target raised to $7 from $6 at H.C. WainwrightMarch 24, 2025 | markets.businessinsider.comEnlivex Therapeutics Secures Patent Allowance in China for Allocetra™ as Treatment for OsteoarthritisMarch 19, 2025 | nasdaq.comEnlivex Therapeutics receives notice of allowance for Chinese patentMarch 17, 2025 | markets.businessinsider.comEnlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with OsteoarthritisMarch 17, 2025 | globenewswire.comEnlivex Announces Positive Interim Data From Early Stage Trial For Osteoarthritis TreatmentMarch 5, 2025 | nasdaq.comEnlivex Therapeutics Ltd. Hosts Investor Webinar to Discuss Positive Interim Data from Allocetra™ Osteoarthritis TrialMarch 4, 2025 | quiverquant.comEnlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee OsteoarthritisMarch 4, 2025 | globenewswire.comEnlivex announces interim 6-month efficacy data from Phase I of Allocetra trialMarch 4, 2025 | markets.businessinsider.comEnlivex Announces Positive Interim Data – Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee OsteoarthritisMarch 3, 2025 | globenewswire.comEnlivex Wins Key Patent in Japan for Osteoarthritis TreatmentFebruary 18, 2025 | tipranks.comEnlivex Therapeutics Ltd: Enlivex Issues Urgent Statement on Fraudulent News DisseminationFebruary 18, 2025 | finanznachrichten.deEnlivex Therapeutics issues statement on ‘fraudulent’ news disseminationFebruary 18, 2025 | markets.businessinsider.comEnlivex Issues Urgent Statement on Fraudulent News DisseminationFebruary 18, 2025 | globenewswire.comEnlivex gains Israeli regulatory approval to commence TMJ osteoarthritis trialDecember 13, 2024 | msn.comEnlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ OsteoarthritisDecember 11, 2024 | globenewswire.comEnlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee OsteoarthritisDecember 5, 2024 | globenewswire.comEnlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee OsteoarthritisDecember 4, 2024 | markets.businessinsider.comEnlivex announces interim efficacy data from Phase I Allocetra trialDecember 4, 2024 | markets.businessinsider.comEnlivex Therapeutics Faces Financial Challenges Amid LossesNovember 29, 2024 | tipranks.comEnlivex Therapeutics adopts Bitcoin treasury reserve strategyNovember 21, 2024 | markets.businessinsider.comEnlivex Therapeutics Ltd. Approves Purchase of Up to $1 Million in Bitcoin as Part of Cash Management StrategyNovember 20, 2024 | quiverquant.comEnlivex Initiates Promising Trial for Psoriatic ArthritisNovember 14, 2024 | markets.businessinsider.comEnlivex completes dosing, follow-up for first patient in study of AllocetraNovember 14, 2024 | markets.businessinsider.comEnlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic ArthritisNovember 14, 2024 | globenewswire.comEnlivex Advances Allocetra Trial for Knee OsteoarthritisNovember 13, 2024 | markets.businessinsider.comEnlivex Therapeutics Reschedules Annual Shareholders MeetingNovember 2, 2024 | markets.businessinsider.comEnlivex Therapeutics receives notice of allowance from Japanese Patent OfficeOctober 31, 2024 | markets.businessinsider.comEnlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra™ in Patients with OsteoarthritisOctober 30, 2024 | globenewswire.comBuy Rating Affirmed for Enlivex as Allocetra™ Advances to Phase 2 with Positive Safety and Diverse PipelineSeptember 27, 2024 | markets.businessinsider.comEnlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee OsteoarthritisSeptember 24, 2024 | globenewswire.comEnlivex Buy Rating Affirmed on Strong Clinical and Financial OutlookSeptember 10, 2024 | markets.businessinsider.comEnlivex Therapeutics Ltd. (ENLV.TA)September 2, 2024 | uk.finance.yahoo.comValneva SE (AYJ0.BE)August 21, 2024 | finance.yahoo.comEnlivex Receives Regulatory Authorization For The Initiation Of A Phase I Clinical Trial To Evaluate Allocetra In Patients With Psoriatic ArthritisJuly 23, 2024 | markets.businessinsider.comEnlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TVJuly 19, 2024 | finanznachrichten.deEnlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee OsteoarthritisJune 17, 2024 | globenewswire.comEnlivex Therapeutics Closes up to $15 Million Registered Direct OfferingMay 29, 2024 | globenewswire.comEnlivex Therapeutics Announces up to $15 Million Registered Direct OfferingMay 28, 2024 | globenewswire.comWe're Keeping An Eye On Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn RateMay 21, 2024 | finance.yahoo.comEnlivex CEO Issues Letter to Shareholders – Perspectives on Recent EventsApril 29, 2024 | finance.yahoo.com Get Enlivex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ENLV and its competitors with MarketBeat's FREE daily newsletter. Email Address ENLV Media Mentions By Week ENLV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ENLV News Sentiment▼0.931.03▲Average Medical News Sentiment ENLV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ENLV Articles This Week▼10▲ENLV Articles Average Week Get Enlivex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ENLV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies XBIT News Today ENTX News Today IVVD News Today CHRS News Today CRDL News Today IMUX News Today ZNTL News Today KYTX News Today ORMP News Today ANIX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ENLV) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enlivex Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enlivex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ENLV Stock Free ENLV Stock Alerts